Working Collaboratively Opportunity – Supporting School Access to Adrenaline Auto-Injectors (AAIs)
key details
| Value | £0 |
|---|---|
| Status | planning |
| Category (CPV) | 33600000 +2 more |
| Region | North East, North West, East Midlands, West Midlands, East of England, South East, South West |
| SME suitable | Yes |
| OCID | ocds-h6vhtk-06d560 |
description
Keeping children and young people with allergies safe while in school is a key priority for the Government. Section 34 of the Children’s Wellbeing and Schools Act 2026 (www.legislation.gov.uk/ukpga/2026/21/section/34/enacted) places new allergy safety duties on schools. We have published new statutory guidance on Allergy safety in schools (www.gov.uk/government/publications/allergy-safety-in-schools). Currently under the Human Medicines (Amendment) Regulations 2017, schools in England are permitted to purchase “spare” adrenaline auto-injectors (AAIs) without a prescription for emergency use in cases of anaphylaxis. The Government intends to require all schools to stock “spare” AAIs. Further education (FE) colleges and other post‑16 institutions are not included in this exemption. Any extension would require regulatory change, which has not yet been implemented. Suppliers should therefore continue to operate in line with the current legal framework.
This early engagement supports the Department for Education’s (DfE) preparatory work ahead of new statutory guidance, with the aim of ensuring schools can access “spare” adrenaline auto-injectors (AAIs) quickly, reliably and affordably to support pupil safety.
The Department is therefore initiating early market engagement with organisations that supply AAIs, including manufacturers, distributors, wholesalers and other authorised suppliers, to better understand the current market landscape and the options available to support schools in accessing “spare” AAIs.
This engagement will inform consideration of a potential working sponsorship approach, through which the provider market may develop voluntary commercial offers directly to schools in return for a rights package. The intention is to support improved affordability, simplify access, and enhance reliability of supply, while maintaining schools’ independence in purchasing decisions.
To inform this approach, the Department is seeking insight into existing routes to market through which schools purchase AAIs, as well as the practical and operational considerations faced by suppliers, delivery models, and any relevant regulatory factors. This includes understanding potential risks or constraints associated with scaling supply at a national level.
The Department intends to hold a market engagement webinar via Microsoft Teams on Tuesday 11 August at 11:30 – 12:00 to provide further context on this initiative. Following this webinar, the Department intends to hold 1-to-1 discussions with interested organisations, to support a more detailed exploration of market capability and gather more detailed insight.
To register your interest in attending this event and/or the 121 discussions, please email Adrenalinedevices.PARTNERSHIP@education.gov.uk before 12:00 on Monday 10 August.
Please note that this notice is for early market engagement and exploratory purposes and is not a call for competition. The Department reserves the right not to enter any formal processes or agreements. Accordingly, the Department will not be liable for any cost, expenditure, work, or effort incurred by a provider in acting based on this notice.
notice history
3 notices published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 28 Jul 2026 | Preliminary market engagement (UK2) | Procurement Act 2023 | 071270-2026 |
| 28 Jul 2026 | Preliminary market engagement (UK2) | Procurement Act 2023 | 071273-2026 |
| 28 Jul 2026 | Preliminary market engagement (UK2) | Procurement Act 2023 | 071351-2026 |
more from Department for Education
- Mathematics Teacher Continuing Professional Development from Reception – A-level · £27,000,000 · 29 Jul 2026
- Future High Potential Initial Teacher Training (HPITT) Programme · £89,000,000 · 23 Jul 2026
- Technical & Vocational Subject Teaching Professional Development · 22 Jul 2026
- Subject Matter Experts for Early Language, Early Maths and Personal, Social and Emotional Development Learning Leads · 21 Jul 2026
- Early Years (EY) Special Educational Needs and Disability (SEND) Continuous Professional Development (CPD) Provision of Phase 1 Materials and Training · £3,166,667 · 17 Jul 2026
- Erasmus+ Government Authorised Exchange Visa Sponsor · £12,118,000 · 17 Jul 2026
- UK4 Notice - Creation of a Lot for Expert Advisers on the ECSC Dynamic Framework · £0 · 17 Jul 2026
- Invitation to Tender for the PE and School Sport Partnership Network · £883,700,000 · 17 Jul 2026
all contracts from this buyer →
similar contracts awarded
Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.
- Radiopharmaceutical Products - Poltech · The Christie NHS Foundation Trust · £39,000
- NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 · NHS England · £592,363,416
- NHS National Generics Pharmaceuticals - Supply Chain Resilience · NHS England · £52,447,296
- Generic, Branded Generic & Proprietary Medicinal Products - Group 18 · Regional Business Services Organisation, Procurement and Logistics Service · £1,800,000,000
- Generic Drugs – Injections/Infusions 2 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £6,535,850
- Transitional Drugs 7 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £53,566,932
- NP90726m Vedolizumab (Entyvio®) · The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) · £47,898,609
- Combined Needles and Syringes Lot 1 · Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · £15,264,000
source
Published on Find a Tender. Contact details for named individuals are not reproduced on this site.